ES2183877T3 - Purina, indol y pirimidina de (dihidroxiboril)alquilo con sustitucion en n, utiles como inhibidores de citoquinas inflamatorias. - Google Patents

Purina, indol y pirimidina de (dihidroxiboril)alquilo con sustitucion en n, utiles como inhibidores de citoquinas inflamatorias.

Info

Publication number
ES2183877T3
ES2183877T3 ES95924657T ES95924657T ES2183877T3 ES 2183877 T3 ES2183877 T3 ES 2183877T3 ES 95924657 T ES95924657 T ES 95924657T ES 95924657 T ES95924657 T ES 95924657T ES 2183877 T3 ES2183877 T3 ES 2183877T3
Authority
ES
Spain
Prior art keywords
indol
purine
pyrimidine
useful
dihidroxiboril
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95924657T
Other languages
English (en)
Inventor
Bradley J Benson
Xiannong Chen
George J Cianciolo
Jose-Luis Diaz
Khalid S Ishaq
Susan L Morris-Natschke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Application granted granted Critical
Publication of ES2183877T3 publication Critical patent/ES2183877T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

SE HA DESCUBIERTO QUE NUEVOS DERIVADOS DE PURINA, INDOL Y PIRIMIDINA (()DIHIDROXIBORILO())ALQUILO N-SUSTITUIDOS, SON UTILES COMO INHIBIDORES DE CITOQUINAS INFLAMATORIAS. PUEDEN SER UTILIZADOS, ENTRE OTRAS, EN LA TERAPIA DE CHOQUE SEPTICO, CAQUEXIA, ARTRITIS REUMATOIDE, TRASTORNO INFLAMATORIO DEL INTESTINO, ESCLEROSIS MULTIPLE Y SIDA. LAS COMPOSICIONES SON TIPICAMENTE PREPARADAS MEDIANTE LA REACCION DE UN ACIDO BROMOALQUILO BORONICO CON LA BASE DE PURINA, INDOL O PIRIMIDINA
ES95924657T 1994-06-22 1995-06-21 Purina, indol y pirimidina de (dihidroxiboril)alquilo con sustitucion en n, utiles como inhibidores de citoquinas inflamatorias. Expired - Lifetime ES2183877T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/264,039 US5643893A (en) 1994-06-22 1994-06-22 N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines

Publications (1)

Publication Number Publication Date
ES2183877T3 true ES2183877T3 (es) 2003-04-01

Family

ID=23004300

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95924657T Expired - Lifetime ES2183877T3 (es) 1994-06-22 1995-06-21 Purina, indol y pirimidina de (dihidroxiboril)alquilo con sustitucion en n, utiles como inhibidores de citoquinas inflamatorias.

Country Status (16)

Country Link
US (1) US5643893A (es)
EP (1) EP0767793B1 (es)
JP (1) JP3805789B2 (es)
KR (1) KR970703975A (es)
AT (1) ATE224396T1 (es)
AU (1) AU2907795A (es)
CA (1) CA2193644A1 (es)
DE (1) DE69528267T2 (es)
DK (1) DK0767793T3 (es)
ES (1) ES2183877T3 (es)
FI (1) FI965141A0 (es)
HU (1) HUT76298A (es)
NO (1) NO965521L (es)
NZ (1) NZ289286A (es)
PT (1) PT767793E (es)
WO (1) WO1995035300A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ502752A (en) * 1997-07-15 2001-01-26 Japan Energy Corp Purine derivatives and their use in the treatment of nephritis
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
BR0012676A (pt) 1999-07-22 2003-07-01 Newbiotics Inc Métodos para tratamento de tumores resistentes a terapia
US6586429B2 (en) * 2000-11-29 2003-07-01 Cell Therapeutics, Inc. Tricyclic fused xanthine compounds and their uses
US7138388B2 (en) * 2001-01-19 2006-11-21 Celmed Oncology (Usa), Inc. Methods to treat autoimmune and inflammatory conditions
CZ20032691A3 (en) * 2001-03-12 2004-04-14 Avanir Pharmaceuticals Benzimidazole compounds for modulating ige and inhibiting cellular proliferation
US20030022864A1 (en) * 2001-04-24 2003-01-30 Ishaq Khalid S. 9-[(5-dihydroxyboryl)-pentyl] purines, useful as an inhibitor of inflammatory cytokines
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2004024655A2 (en) * 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
CA2515530A1 (en) * 2003-02-11 2004-08-26 Boehringer Ingelheim International Gmbh New pharmaceutical compositions based on anticholinergics and inhibitors of tnf alpha synthesis or action
EP1651198A2 (en) * 2003-08-08 2006-05-03 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
MY146066A (en) * 2004-07-01 2012-06-29 Microlin L C Device employing gas generating cell for facilitating controlled release of fluid into ambient environment
WO2007134169A2 (en) * 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US20090264384A1 (en) * 2004-11-01 2009-10-22 Nuada, Inc. Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
EP1812451A4 (en) * 2004-11-01 2009-10-21 Nuada Llc COMPOUNDS AND METHODS OF USE THEREOF
US20080269204A1 (en) * 2004-11-01 2008-10-30 Tatyana Dyakonov Compounds and Methods of Use Thereof
US20080319044A1 (en) * 2004-11-01 2008-12-25 Nuada, Llc Compounds and Methods of Use Thereof
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
AU2009234373B2 (en) * 2008-04-09 2015-09-24 Cornell University Coferons and methods of making and using them
CA2721060A1 (en) * 2008-04-09 2009-10-15 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118155A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
CA2774476A1 (en) 2009-10-07 2011-04-14 Francis Barany Coferons and methods of making and using them
RU2015143910A (ru) 2010-02-03 2018-12-28 Инфинити Фармасьютикалз, Инк. Ингибиторы амид-гидролазы жирных кислот
EP2647639A1 (en) * 2012-04-06 2013-10-09 LEK Pharmaceuticals d.d. ß-boration of alkene and alkyne intermediates
EP3362462B1 (en) 2015-10-12 2021-07-21 Advanced Cell Diagnostics, Inc. In situ detection of nucleotide variants in high noise samples, and compositions and methods related thereto
IL319437A (en) 2022-09-07 2025-05-01 Mdx Man Llc Shp-1 inhibitors for treating cancer
WO2024097804A1 (en) 2022-11-02 2024-05-10 Mdx Management Llc Combination of a tyrosine kinase inhibitor and a pro-inflammatory agent for treating cancer
AU2024239074A1 (en) 2023-03-17 2025-10-02 Mdx Management Llc Compositions and methods for ameliorating adverse effects of therapies
WO2025038745A1 (en) 2023-08-16 2025-02-20 Mdx Management Llc Compositions and methods for activating immune cells
WO2025188920A1 (en) 2024-03-06 2025-09-12 Mdx Management Llc Local application of agents inhibiting tyrosine kinase or shp-1 signaling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
US4537773A (en) * 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
GB8926611D0 (en) * 1989-11-24 1990-01-17 Xenova Ltd Compound and its use
US5130302A (en) * 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5362732A (en) * 1989-12-20 1994-11-08 University Of North Carolina At Chapel Hill Boronated compounds
EP0584347B1 (en) * 1992-03-04 2003-01-15 Cell Therapeutics, Inc. Enantiomeric hydroxylated xanthine compounds
US5306722A (en) * 1992-09-02 1994-04-26 Bristol-Myers Squibb Company Thymidine derivatives and therapeutic method of use

Also Published As

Publication number Publication date
FI965141L (fi) 1996-12-20
US5643893A (en) 1997-07-01
PT767793E (pt) 2003-02-28
KR970703975A (ko) 1997-08-09
JP3805789B2 (ja) 2006-08-09
DK0767793T3 (da) 2002-10-14
HUT76298A (en) 1997-07-28
EP0767793A1 (en) 1997-04-16
DE69528267D1 (de) 2002-10-24
NO965521D0 (no) 1996-12-20
EP0767793B1 (en) 2002-09-18
DE69528267T2 (de) 2003-04-17
HU9603536D0 (en) 1997-02-28
NZ289286A (en) 1998-09-24
CA2193644A1 (en) 1995-12-28
JPH10507739A (ja) 1998-07-28
NO965521L (no) 1997-02-21
AU2907795A (en) 1996-01-15
ATE224396T1 (de) 2002-10-15
FI965141A7 (fi) 1996-12-20
FI965141A0 (fi) 1996-12-20
WO1995035300A1 (en) 1995-12-28

Similar Documents

Publication Publication Date Title
ES2183877T3 (es) Purina, indol y pirimidina de (dihidroxiboril)alquilo con sustitucion en n, utiles como inhibidores de citoquinas inflamatorias.
NO20001583D0 (no) Stimulering av hematopoetiske celler in vitro
TR200102800T2 (tr) Yeni bileşikler.
FI971953A0 (fi) Proteiinityrosiinikinaasin välittämää soluproliferaatiota inhiboivat 6-aryyli-pyrido(2,3-d)pyrimidiinit ja naftyridiinit
ES8504128A1 (es) Procedimiento de preparar compuestos antiinflamatorios y anti-alergicos
FI964004A0 (fi) Serotoniiniantagonistien (5HT3) käyttö fibromyalgian hoitoon
ES2174895T3 (es) Combinaciones metalicas complejas con contenido en carbenos heterociclicos.
MX9203018A (es) Fluoroalcoxibencilamino-derivados de heterociclos nitrogenados.
NO983189L (no) Nye substituerte imidazolforbindelser
AR010062A1 (es) Nuevos benzamidaldehidos y su utilizacion
ES2075247T3 (es) Sales de amonio del acido n(5)-metil-5,6,7,8-tetrahidrofolico.
ES8707485A1 (es) Un metodo para preparar 6-hidroxi-2-acetilnaftaleno
ES8203375A1 (es) Procedimiento de preparar triazoloquinoxalin-4-onas substi- tuidas antihipertensoras
ES2060818T3 (es) Derivados de indol, benzofurano y benzotiofeno sustituidos como inhibidores de la 5-lipooxigenasa.
ES2058191T3 (es) Acidos 2-fenil-4-quinolincarboxilicos substituidos.
BG42185A3 (en) Method for preparing pyridylic compounds
BG104291A (en) 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use
ES2092751T3 (es) Nuevos 2-sacarinilmetil aril carboxilatos utiles como inhibidores de enzimas proteoliticos y composiciones y metodos de empleo de los mismos.
YU45690B (sh) Postopek za pripravo 9-(2-hidroksietoksimetil)-gvanina
ES2126575T3 (es) Sacarosa-fosfato-sintasa (sps), su procedimiento de preparacion, su adnc, y utilizacion de adnc para modificar la expresion de sps en celulas vegetales.
ES2102295B1 (es) Nuevos compuestos derivados de la n-benzoilmetil-piperidina.
BG40808A3 (bg) Метод за получаване на производни на пиролидина
ES2058372T3 (es) Procedimiento para la obtencion de esteres del acido 5-cloro-3-clorosulfonil-2-tiofenocarboxilico.
BG37380A3 (en) Method for preparing 1, 1- dioxo- 6- halo (or 6, 6- dihalo)- penicillanoyloxymethylic ester of 6- (2- amino- 2- phenylacetamido) penicillanic acid
BG40653A3 (en) Method for preparing amidothiocarbamate derivatives of carbon acid